Oric Pharmaceuticals reports third quarter 2025 financial results and updates on clinical programs
Oric Pharmaceuticals Inc reported cash, cash equivalents, and investments totaling $413.0 million as of September 30, 2025, supported by a $125.0 million private placement and $117.6 million in net proceeds from an ATM program. Research and development expenses were $28.8 million for the third quarter of 2025, down from $31.2 million in the same period of 2024, primarily due to lower drug manufacturing costs for ORIC-944 and discontinued programs, partially offset by increased personnel and enozertinib advancement costs. For the nine months ended September 30, 2025, R&D expenses rose to $84.0 million from $82.1 million in the prior year period. General and administrative expenses were $7.9 million for the third quarter of 2025, up from $7.1 million in the prior year. The company expects its cash position to fund operations into the second half of 2028. Oric completed dose exploration in the ORIC-944 Phase 1b clinical trial and plans four clinical data readouts across its ORIC-944 and enozertinib programs through mid-2026, ahead of potential Phase 3 trial initiations in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-280196), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.